Beta‑Blocker Therapy in Systolic Heart Failure

Indications and Patient Selection

• All stable patients with heart failure with reduced ejection fraction (HFrEF) should be started on an evidence‑based beta‑blocker (bisoprolol, carvedilol, or metoprolol succinate) as soon as the diagnosis is made, even if symptoms are mild or have improved with other drugs; mortality benefit is independent of symptom status【@1】.
• Required stability before initiation: no intensive‑care unit admission, euvolemic on stable diuretic regimen, and no recent intravenous inotropic therapy【@1】【@4】.
• High‑dose ACE‑inhibitor therapy is not a prerequisite; adding a beta‑blocker to a low‑dose ACE inhibitor yields greater mortality reduction than up‑titrating the ACE inhibitor alone【@1】【@2】.

Choice of Beta‑Blocker and Target Doses

• Metoprolol tartrate (immediate‑release) and bucindolol have not shown mortality benefit and should be avoided in HFrEF【@1】.

Initiation and Titration Protocol

• Begin with the very low dose listed above and double the dose every 2 weeks if tolerated, monitoring heart rate, blood pressure, congestion signs, fatigue/dizziness, and basic chemistries at each step【@1】.
• Approximately 85 % of patients can reach the target doses with this cautious titration【@1】.

Expected Mortality Benefit

• Achieving the trial target doses of the three beta‑blockers reduces all‑cause mortality by 34–35 %【@1】【@2】.
• If target doses are not tolerated, aim for at least 50 % of the target dose; any beta‑blocker dose is preferable to none【@3】.

Contraindications

Absolute contraindications

• Recent (within 4 weeks) decompensated HF requiring hospitalization【@1】.
• Need for intravenous inotropic therapy【@4】.
• Second‑ or third‑degree AV block without a pacemaker【@3】.
• Symptomatic hypotension【@2】.
• Active asthma with persistent symptoms【@1】.

Relative contraindications

• Reactive airway disease or asymptomatic bradycardia may be used with close monitoring【@1】.

Management of Common Adverse Reactions

• Fluid retention / worsening HF – first increase diuretic dose; if congestion persists, halve the beta‑blocker dose (do not permanently discontinue)【@3】.
• Fatigue – halve the beta‑blocker dose【@3】.
• Symptomatic bradycardia (<50 bpm with symptoms) – halve the dose; seek specialist input if severe deterioration occurs【@3】.
• Symptomatic hypotension – sequentially reduce/stop nitrates, calcium‑channel blockers, and other vasodilators; then reduce diuretic if no congestion; finally halve the beta‑blocker dose if needed【@3】.

Long‑Term Management

• Continue beta‑blocker therapy indefinitely to sustain mortality benefit and prevent disease progression, even in patients with minimal symptoms【@1】【@2】.
• Educate patients to weigh themselves daily and increase diuretic dose if weight rises by 1.5–2.0 kg over two consecutive days【@3】.

Background Therapy Requirements

• Beta‑blockers should be added to mandatory diuretics when any history of fluid retention exists【@1】【@2】.
• Standard background neurohormonal blockade includes an ACE inhibitor, ARB, or ARNI【@2】.
• Digoxin may be continued if already prescribed【@4】.
• The combination of a beta‑blocker with an ACE inhibitor provides additive mortality reduction through dual neurohormonal blockade【@2】.